Loading…
Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide
Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem). Retrospective data of patients with Pan...
Saved in:
Published in: | BMC cancer 2024-11, Vol.24 (1), p.1362-10, Article 1362 |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c510t-86f77a5d7af7954a221ec37221f858f95e0eab9a2285e7fdf40994665289bfeb3 |
container_end_page | 10 |
container_issue | 1 |
container_start_page | 1362 |
container_title | BMC cancer |
container_volume | 24 |
creator | Gao, Heli Zhang, Wuhu Li, Zheng Liu, Wensheng Liu, Mengqi Zhuo, Qifeng Shi, Yihua Xu, Wenyan Zhou, Chenjie Qin, Yi Xu, Jin Chen, Jie Yu, Xianjun Xu, Xiaowu Ji, Shunrong |
description | Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).
Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.
In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p |
doi_str_mv | 10.1186/s12885-024-13117-5 |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_07be9ba86f7a4a8dbe7f208d56ee4cc4</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A815234573</galeid><doaj_id>oai_doaj_org_article_07be9ba86f7a4a8dbe7f208d56ee4cc4</doaj_id><sourcerecordid>A815234573</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-86f77a5d7af7954a221ec37221f858f95e0eab9a2285e7fdf40994665289bfeb3</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rr6B7yQgCB60bVpmya9kmX9GlwQ_LgOp8npTIY2mU3SYfW_-F9NZ9Z1RiQXCSfPeUPe82bZU1qcUyqa14GWQrC8KOucVpTynN3LTmnNaV7WBb9_cD7JHoWwLgrKRSEeZidVyyhljJ1mv96aEI1V0WyRLD1oJB0E1MRZ8sk0nBir8YaA1cSM42SRjEZ5h3ZrvLMj2khcT0aMECJEo8gGrPK4O1qcZlI75U1qjNPofCAew8ZZbeySREcUbFCZCN1MbIYpkIij--kGNxqNj7MHPQwBn9zuZ9n39---XX7Mrz5_WFxeXOWK0SLmouk5B6Y59LxlNZQlRVXxtPWCib5lWCB0baoLhrzXfV20bd00rBRt12NXnWWLva52sJYbb0bwP6QDI3cF55cSfPrSgLLgHbYdzE9CDUJ3SbAshGYNYq1UnbTe7LU2UzeiVskiD8OR6PGNNSu5dFuZJlKXlWiTwstbBe-uJwxRjiYoHAaw6KYgqzT3qmRlyxL6_B907SZvk1cz1dQpAaz9Sy0h_cDY3qWH1SwqLwRlZVUzXiXq_D9UWhrTzJ3F3qT6UcOro4bERLyJS5hCkIuvX47ZFwfsCmGIq-CGKRpnwzFY7sGUshA89nfO0ULOsZf72MsUe7mLvZxteHbo-V3Ln5xXvwHT-v9L</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3126414759</pqid></control><display><type>article</type><title>Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Gao, Heli ; Zhang, Wuhu ; Li, Zheng ; Liu, Wensheng ; Liu, Mengqi ; Zhuo, Qifeng ; Shi, Yihua ; Xu, Wenyan ; Zhou, Chenjie ; Qin, Yi ; Xu, Jin ; Chen, Jie ; Yu, Xianjun ; Xu, Xiaowu ; Ji, Shunrong</creator><creatorcontrib>Gao, Heli ; Zhang, Wuhu ; Li, Zheng ; Liu, Wensheng ; Liu, Mengqi ; Zhuo, Qifeng ; Shi, Yihua ; Xu, Wenyan ; Zhou, Chenjie ; Qin, Yi ; Xu, Jin ; Chen, Jie ; Yu, Xianjun ; Xu, Xiaowu ; Ji, Shunrong</creatorcontrib><description>Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).
Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.
In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p < 0.001).
Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-024-13117-5</identifier><identifier>PMID: 39511555</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biopsy ; Capecitabine - administration & dosage ; Capecitabine - therapeutic use ; Capecitabine/temozolomide ; Care and treatment ; CD11b antigen ; CD163 antigen ; CD25 antigen ; CD4 antigen ; CD80 antigen ; CD86 antigen ; Chemotherapy ; Development and progression ; Diagnosis ; Dosage and administration ; Female ; Humans ; Immunofluorescence ; Immunoregulation ; Ki-67 Antigen - metabolism ; Ki67 index ; Liver ; Lymphocytes T ; Macrophages ; Male ; Medical prognosis ; Metastases ; Metastasis ; Microenvironments ; Middle Aged ; Neoplasm Grading ; Neuroendocrine tumors ; Neuroendocrine Tumors - drug therapy ; Neuroendocrine Tumors - immunology ; Neuroendocrine Tumors - pathology ; Pancreas ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - immunology ; Pancreatic Neoplasms - pathology ; Pancreatic neuroendocrine tumor ; Pancreatic tumors ; Patients ; Retrospective Studies ; Suppressor cells ; Surgery ; Temozolomide ; Temozolomide - administration & dosage ; Temozolomide - pharmacology ; Temozolomide - therapeutic use ; Testing ; Treatment Outcome ; Tumor antigens ; Tumor microenvironment ; Tumor Microenvironment - drug effects ; Tumor Microenvironment - immunology ; Upgrading ; Variance analysis</subject><ispartof>BMC cancer, 2024-11, Vol.24 (1), p.1362-10, Article 1362</ispartof><rights>2024. The Author(s).</rights><rights>COPYRIGHT 2024 BioMed Central Ltd.</rights><rights>2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c510t-86f77a5d7af7954a221ec37221f858f95e0eab9a2285e7fdf40994665289bfeb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542389/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3126414759?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39511555$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Heli</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Liu, Wensheng</creatorcontrib><creatorcontrib>Liu, Mengqi</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Shi, Yihua</creatorcontrib><creatorcontrib>Xu, Wenyan</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Xu, Jin</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><title>Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).
Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.
In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p < 0.001).
Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.</description><subject>Adult</subject><subject>Aged</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biopsy</subject><subject>Capecitabine - administration & dosage</subject><subject>Capecitabine - therapeutic use</subject><subject>Capecitabine/temozolomide</subject><subject>Care and treatment</subject><subject>CD11b antigen</subject><subject>CD163 antigen</subject><subject>CD25 antigen</subject><subject>CD4 antigen</subject><subject>CD80 antigen</subject><subject>CD86 antigen</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Female</subject><subject>Humans</subject><subject>Immunofluorescence</subject><subject>Immunoregulation</subject><subject>Ki-67 Antigen - metabolism</subject><subject>Ki67 index</subject><subject>Liver</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neuroendocrine tumors</subject><subject>Neuroendocrine Tumors - drug therapy</subject><subject>Neuroendocrine Tumors - immunology</subject><subject>Neuroendocrine Tumors - pathology</subject><subject>Pancreas</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - immunology</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic neuroendocrine tumor</subject><subject>Pancreatic tumors</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Suppressor cells</subject><subject>Surgery</subject><subject>Temozolomide</subject><subject>Temozolomide - administration & dosage</subject><subject>Temozolomide - pharmacology</subject><subject>Temozolomide - therapeutic use</subject><subject>Testing</subject><subject>Treatment Outcome</subject><subject>Tumor antigens</subject><subject>Tumor microenvironment</subject><subject>Tumor Microenvironment - drug effects</subject><subject>Tumor Microenvironment - immunology</subject><subject>Upgrading</subject><subject>Variance analysis</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkl2L1DAUhoso7rr6B7yQgCB60bVpmya9kmX9GlwQ_LgOp8npTIY2mU3SYfW_-F9NZ9Z1RiQXCSfPeUPe82bZU1qcUyqa14GWQrC8KOucVpTynN3LTmnNaV7WBb9_cD7JHoWwLgrKRSEeZidVyyhljJ1mv96aEI1V0WyRLD1oJB0E1MRZ8sk0nBir8YaA1cSM42SRjEZ5h3ZrvLMj2khcT0aMECJEo8gGrPK4O1qcZlI75U1qjNPofCAew8ZZbeySREcUbFCZCN1MbIYpkIij--kGNxqNj7MHPQwBn9zuZ9n39---XX7Mrz5_WFxeXOWK0SLmouk5B6Y59LxlNZQlRVXxtPWCib5lWCB0baoLhrzXfV20bd00rBRt12NXnWWLva52sJYbb0bwP6QDI3cF55cSfPrSgLLgHbYdzE9CDUJ3SbAshGYNYq1UnbTe7LU2UzeiVskiD8OR6PGNNSu5dFuZJlKXlWiTwstbBe-uJwxRjiYoHAaw6KYgqzT3qmRlyxL6_B907SZvk1cz1dQpAaz9Sy0h_cDY3qWH1SwqLwRlZVUzXiXq_D9UWhrTzJ3F3qT6UcOro4bERLyJS5hCkIuvX47ZFwfsCmGIq-CGKRpnwzFY7sGUshA89nfO0ULOsZf72MsUe7mLvZxteHbo-V3Ln5xXvwHT-v9L</recordid><startdate>20241107</startdate><enddate>20241107</enddate><creator>Gao, Heli</creator><creator>Zhang, Wuhu</creator><creator>Li, Zheng</creator><creator>Liu, Wensheng</creator><creator>Liu, Mengqi</creator><creator>Zhuo, Qifeng</creator><creator>Shi, Yihua</creator><creator>Xu, Wenyan</creator><creator>Zhou, Chenjie</creator><creator>Qin, Yi</creator><creator>Xu, Jin</creator><creator>Chen, Jie</creator><creator>Yu, Xianjun</creator><creator>Xu, Xiaowu</creator><creator>Ji, Shunrong</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241107</creationdate><title>Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide</title><author>Gao, Heli ; Zhang, Wuhu ; Li, Zheng ; Liu, Wensheng ; Liu, Mengqi ; Zhuo, Qifeng ; Shi, Yihua ; Xu, Wenyan ; Zhou, Chenjie ; Qin, Yi ; Xu, Jin ; Chen, Jie ; Yu, Xianjun ; Xu, Xiaowu ; Ji, Shunrong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-86f77a5d7af7954a221ec37221f858f95e0eab9a2285e7fdf40994665289bfeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biopsy</topic><topic>Capecitabine - administration & dosage</topic><topic>Capecitabine - therapeutic use</topic><topic>Capecitabine/temozolomide</topic><topic>Care and treatment</topic><topic>CD11b antigen</topic><topic>CD163 antigen</topic><topic>CD25 antigen</topic><topic>CD4 antigen</topic><topic>CD80 antigen</topic><topic>CD86 antigen</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Female</topic><topic>Humans</topic><topic>Immunofluorescence</topic><topic>Immunoregulation</topic><topic>Ki-67 Antigen - metabolism</topic><topic>Ki67 index</topic><topic>Liver</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neuroendocrine tumors</topic><topic>Neuroendocrine Tumors - drug therapy</topic><topic>Neuroendocrine Tumors - immunology</topic><topic>Neuroendocrine Tumors - pathology</topic><topic>Pancreas</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - immunology</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic neuroendocrine tumor</topic><topic>Pancreatic tumors</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Suppressor cells</topic><topic>Surgery</topic><topic>Temozolomide</topic><topic>Temozolomide - administration & dosage</topic><topic>Temozolomide - pharmacology</topic><topic>Temozolomide - therapeutic use</topic><topic>Testing</topic><topic>Treatment Outcome</topic><topic>Tumor antigens</topic><topic>Tumor microenvironment</topic><topic>Tumor Microenvironment - drug effects</topic><topic>Tumor Microenvironment - immunology</topic><topic>Upgrading</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Heli</creatorcontrib><creatorcontrib>Zhang, Wuhu</creatorcontrib><creatorcontrib>Li, Zheng</creatorcontrib><creatorcontrib>Liu, Wensheng</creatorcontrib><creatorcontrib>Liu, Mengqi</creatorcontrib><creatorcontrib>Zhuo, Qifeng</creatorcontrib><creatorcontrib>Shi, Yihua</creatorcontrib><creatorcontrib>Xu, Wenyan</creatorcontrib><creatorcontrib>Zhou, Chenjie</creatorcontrib><creatorcontrib>Qin, Yi</creatorcontrib><creatorcontrib>Xu, Jin</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Yu, Xianjun</creatorcontrib><creatorcontrib>Xu, Xiaowu</creatorcontrib><creatorcontrib>Ji, Shunrong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Heli</au><au>Zhang, Wuhu</au><au>Li, Zheng</au><au>Liu, Wensheng</au><au>Liu, Mengqi</au><au>Zhuo, Qifeng</au><au>Shi, Yihua</au><au>Xu, Wenyan</au><au>Zhou, Chenjie</au><au>Qin, Yi</au><au>Xu, Jin</au><au>Chen, Jie</au><au>Yu, Xianjun</au><au>Xu, Xiaowu</au><au>Ji, Shunrong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2024-11-07</date><risdate>2024</risdate><volume>24</volume><issue>1</issue><spage>1362</spage><epage>10</epage><pages>1362-10</pages><artnum>1362</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>Ki67 index changes during the treatment of metastatic pancreatic neuroendocrine tumor (PanNET) treatment. The study aimed to detect alterations of grade based on Ki67 index and immune microenvironment in PanNET responding to capecitabine/temozolomide (CapTem).
Retrospective data of patients with PanNET were collected. In control group, 35 patients underwent surgery immediately after biopsy. In CapTem group, 38 patients received CapTem after biopsy and responded well to treatment (defined as either stable disease or partial response), and subsequently underwent surgery. All patients have pathological Ki67 index at biopsy and after surgery. CD163 + CD68 + CD206 + M2 macrophages, CD68 + CD86 + CD80 + M1 macrophages, CD11b + CD33 + myeloid-derived suppressor cells, and CD4 + CD25 + regulatory T cells were stained using multiplex immunofluorescence.
In control group, the paired grade based on Ki67 index directly after surgery showed no upgrade or downgrade compared to biopsy. In patients who responded well to CapTem, the grade based on Ki67 index before and after CapTem was altered. Thirteen patients had upgraded Ki67 index and 11 patients had downgraded. The proportion of stable disease was higher in the upgraded group compared to downgraded group (p = 0.0155). And upgraded group had a significantly shorter mPFS than patients in the downgrade group (8.5 months vs. 20 months, HR 4.834, 95% CI 1.414 to 16.53, p = 0.012). M1 macrophages was significantly lower in the downgraded group than in the Ki67 upgraded group (p < 0.001).
Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>39511555</pmid><doi>10.1186/s12885-024-13117-5</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2407 |
ispartof | BMC cancer, 2024-11, Vol.24 (1), p.1362-10, Article 1362 |
issn | 1471-2407 1471-2407 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_07be9ba86f7a4a8dbe7f208d56ee4cc4 |
source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
subjects | Adult Aged Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biopsy Capecitabine - administration & dosage Capecitabine - therapeutic use Capecitabine/temozolomide Care and treatment CD11b antigen CD163 antigen CD25 antigen CD4 antigen CD80 antigen CD86 antigen Chemotherapy Development and progression Diagnosis Dosage and administration Female Humans Immunofluorescence Immunoregulation Ki-67 Antigen - metabolism Ki67 index Liver Lymphocytes T Macrophages Male Medical prognosis Metastases Metastasis Microenvironments Middle Aged Neoplasm Grading Neuroendocrine tumors Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - immunology Neuroendocrine Tumors - pathology Pancreas Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - immunology Pancreatic Neoplasms - pathology Pancreatic neuroendocrine tumor Pancreatic tumors Patients Retrospective Studies Suppressor cells Surgery Temozolomide Temozolomide - administration & dosage Temozolomide - pharmacology Temozolomide - therapeutic use Testing Treatment Outcome Tumor antigens Tumor microenvironment Tumor Microenvironment - drug effects Tumor Microenvironment - immunology Upgrading Variance analysis |
title | Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A03%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Distinctive%20grade%20based%20on%20Ki67%20index%20and%20immune%20microenvironment%20of%20metastatic%20pancreatic%20neuroendocrine%20tumors%20responding%20to%20capecitabine%20plus%20temozolomide&rft.jtitle=BMC%20cancer&rft.au=Gao,%20Heli&rft.date=2024-11-07&rft.volume=24&rft.issue=1&rft.spage=1362&rft.epage=10&rft.pages=1362-10&rft.artnum=1362&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-024-13117-5&rft_dat=%3Cgale_doaj_%3EA815234573%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c510t-86f77a5d7af7954a221ec37221f858f95e0eab9a2285e7fdf40994665289bfeb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3126414759&rft_id=info:pmid/39511555&rft_galeid=A815234573&rfr_iscdi=true |